Samsung Biologics (207940.KS) Financial Analysis & Valuation | Quarter Chart
Samsung Biologics (207940.KS)
207940.KSPrice: $902.09
Fair Value: 🔒
🔒score
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstr... more
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for bio... more
Description
Shares
| Market Cap | $41.76B | Exchange | KSC |
| Sector | Healthcare | Industry | Biotechnology |
| Country | KR | CEO | John Chongbo Rim |
| IPO Date | 2016-11-11 | CAGR | 0.41% |
| Employees | 4,770 | Website | samsungbiologics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.18% | Total Yield | 0.18% |
207940.KS chart loading...
Fundamentals
Technicals
| Enterprise Value | $70217.77B | P/E Ratio | 40.32 |
| Forward P/E | 30.04 | PEG Ratio | — |
| P/S Ratio | 11.23 | P/B Ratio | 6.41 |
| P/CF Ratio | 21.75 | P/FCF Ratio | 34.81 |
| EPS | $22.37 | EPS Growth 1Y | 46.86% |
| EPS Growth 3Y | 136.66% | EPS Growth 5Y | 565.43% |
| Revenue Growth 1Y | -7.82% | Gross Margin | 0.56% |
| Operating Margin | 0.42% | Profit Margin | 0.42% |
| ROE | 0.19% | ROA | 0.16% |
| ROCE | 0.2% | Current Ratio | 1.7 |
| Quick Ratio | 0.86 | Cash Ratio | 0.19 |
| Debt/Equity | 0.15 | Interest Coverage | 71.07 |
| Altman Z Score | 11.59 | Piotroski Score | 8 |